Quality prescribing for respiratory illness 2024 to 2027 - draft guidance: consultation

References

1. Scottish Government, 2021. Respiratory Care Action Plan. 2021- 2026 Respiratory care - action plan: 2021 to 2026 - gov.scot (www.gov.scot) (Accessed 12 October 2022)

2. Scottish Government, 2021. Scottish Health Survey Scottish Health Survey - gov.scot (www.gov.scot) (Accessed 12 October 2022)

3. World Health Organisation, 2020. WHO package of essential noncommunicable (PEN) disease intervention for primary health care. WHO package of essential noncommunicable (PEN) disease interventions for primary health care (Accessed 12 October 2022

4. Scottish Government, 2022. Realistic Medicine Realistic Medicine – Shared decision making, reducing harm, waste and tackling unwarranted variation (accessed 12 October 2022)

5. Scottish Government, 2018. Polypharmacy Model of care Group. Polypharmacy Guidance Realistic Prescribing 3^rd Edition Polypharmacy – Effective Prescribing and Therapeutics (scot.nhs.uk) (Accessed 12 October 2022)

6. Scottish Government, 2022. NHS Scotland Climate emergency and suitability strategy: 2022-2026 https://www.gov.scot/publications/nhs-scotland-climate-emergency-sustainability-strategy-2022-2026 (Accessed: 12 October 2022)

7. Scottish Government, 2022. Polypharmacy: Manage Medicines - Respiratory Prescribing Polypharmacy: Manage Medicines (scot.nhs.uk) (Accessed 12 October 2022)

8. Grol, R and Grimshaw, J. From best evidence to best practice: effective implementation of change in patients' care, The Lancet, Volume 362, Issue 9391, 2003, Pages 1225-1230, ISSN 0140-6736 https://doi.org/10.1016/S0140-6736(03)14546-1 (Accessed 12 October 2022)

9. Health Improvement Scotland, 2022. Why ask what matters? What matters to you? (Accessed 12 October 2022)

10. Public Health Scotland, 2021. Dispenser payments and prescription cost analysis. Dispenser payments and prescription cost analysis - financial year 2020 to 2021 - Dispenser payments and prescription cost analysis - Publications - Public Health Scotland (Accessed 12 October 2022)

11. National Institute for Health and Clinical Excellence. Clinical Knowledge Summary- Asthma ‘What is the prevalence of Asthma’ (2022 update) https://cks.nice.org.uk/topics/asthma/background-information/prevalence/(Accessed: 12 October 2022).

12. Scottish Intercollegiate Guidelines Network / British Thoracic Society (BTS), 2019. British Guideline on the Management of Asthma SIGN 158. British guideline on the management of asthma (sign.ac.uk) (Accessed: 12 October 2022).

13. Health Improvement Scotland, 2021. Steroid emergency card Steroid Emergency Card to support early recognition and treatment of adrenal crisis in adults: July 2021 (healthcareimprovementscotland.org) (Accessed 12 October 2022)

14. National Institute for Health and Clinical Excellence, 2021. Clinical Knowledge Summary. Osteoporosis – prevention of fragility factures Osteoporosis - prevention of fragility fractures | Health topics A to Z | CKS | NICE (accessed 12 October 2022)

15. GSK, 2021. Asthma Control Test, 2021 https://www.asthmacontroltest.com/en-gb/welcome/ (Accessed 12 October2022)

16. Royal College of Physicians. National Review of Asthma Deaths (NRAD) Confidential Enquiry report. London: RCP, 2014 https://www.rcplondon.ac.uk/projects/national-review-asthma-deaths(Accessed 12 October 2022)

17. Primary Care Respiratory Society, 2022. Online Asthma Slide rule https://www.pcrs-uk.org/resource/online-asthma-slide-rule (Accessed 12 October 2022)

18. Janson, C et al. An Overview of Short Acting B₂ Agonist Use in Asthma in European Countries, Advances in Therapy 2020. March; 37 (3): p1124-1135, doi: 10.1007/s12325-020-01233-0 SABINA: An Overview of Short-Acting β2-Agonist Use in Asthma in European Countries - PubMed (nih.gov) Accessed 12 October 2022)

19. General Pharmaceutical Council Patient safety spotlight, 2022. The risks of overprescribing Salbutamol inhalers for asthma https://www.pharmacyregulation.org/regulate/article/patient-safety-spotlight-risks-overprescribing-salbutamol-inhalers-asthma (accessed 12 October 2022)

20. Conner J & Buck P. Improving Asthma Management: The Case for Mandatory Inclusion of Dose Counters on All Rescue Bronchodilators. Journal of Asthma 2013 Aug; 50 (6) :658-663 doi: 10.3109/02770903.2013.789056 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3741013/ (Accessed 12 October 2022)

21. Janson C, et al. The carbon footprint of respiratory treatment in Europe and Canada: an observational study from the CARBON programme. European Respiratory Journal 2022. June (60): 2102760 https://erj.ersjournals.com/content/60/2/2102760(accessed 18 October 2022) DOI: 10.1183/13993003.02760-2021

22. Eurostat Respiratory disease statistics. Respiratory diseases statistics - Statistics Explained (europa.eu) (accessed 26 October 2022)

23. Chiesi, 2019. Clenil^® Modulite^® 250 micrograms inhaler (with dose counter) SmPC. Available at https://www.medicines.org.uk/emc/product/6977/smpc (accessed 18 October 2022)

24. Kankaanranta, Hannu & Lahdensuo, Aarne & Moilanen, Eeva & Barnes, Peter. (2004). Add-on therapy options in asthma not adequately controlled by inhaled corticosteroids: A comprehensive review. Respiratory research. 5. 17. 10.1186/1465-9921-5-17. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC528858/ (accessed 9^th November 2022)

25. Joint Formulary Committee, 2022. British National Formulary online. Montelukast updated 2022. https://bnf.nice.org.uk/drugs/montelukast/ (accessed 18 October 2022)

26. Medicines and Healthcare products Regulatory Agency, 2019. Montelukast (Singulair): reminder of the risk of neuropsychiatric reactions. Available at https://www.gov.uk/drug-safety-update/montelukast-singulair-reminder-of-the-risk-of-neuropsychiatric-reactions (accessed 18 October 2022)

27. European Medicines Agency, 2022. Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation- Montelukast July 2019. Available at Montelukast: CMDh scientific conclusions and grounds for the variation, amendments to the product information and timetable for the implementation - PSUSA/00002087/201807 (europa.eu) accessed 18 October 2022)

28. Global Initiative for Asthma, 2022. GINA Difficult to treat & severe asthma Guide 2022. Available at https://ginasthma.org/reports/ (accessed 19 October 2022)

29. Asthma UK, 2019. Living in Limbo: the scale of unmet need in difficult and severe asthma. available at https://www.asthma.org.uk/69841483/globalassets/get-involved/external-affairs-campaigns/publications/living-in-limbo/living-in-limbo---the-scale-of-unmet-need-in-difficult-and-severe-asthma.pdf (accessed 18 October 2022)

30. PRECISION Scotland National Working Group. Severe asthma patient pathway for Scotland. March 2022 (funded by AstraZeneca and the PRECISION programme)

31. Health Improvement Scotland Scottish Medicines Consortium, 2022. Omalizumab 7mg, 150mg solution for injection (Xolair) Advice, June 2011. Available at https://www.scottishmedicines.org.uk/medicines-advice/omalizumab-75mg-150mg-solution-for-injection-xolair-abbreviatedsubmission-70811/ (accessed 18 October 2022)

32. Health Improvement Scotland Scottish Medicines Consortium, 2022. Mepolizumab (Nucala) Advice, June 2016. Available at https://www.scottishmedicines.org.uk/medicines-advice/mepolizumab-nucala-fullsubmission-114916(accessed 18 October 2022)

33. Health Improvement Scotland / Scottish Medicines Consortium, 2022. Benralizumab (Fasenra) Advice, June 2019. Available at https://www.scottishmedicines.org.uk/medicines-advice/benralizumab-fasenra-fullsubmission-smc2155/ (accessed 18 October 2022)

34. Health Improvement Scotland / Scottish Medicines Consortium, 2022. Dupilumab (Dupixent) Advice, April 2021. Available at https://www.scottishmedicines.org.uk/medicines-advice/dupilumab-dupixent-full-smc2317/(accessed 18 October 2022)

35. National Institute of Clinical Excellence, 2021 Asthma: Diagnosis, monitoring and chronic asthma management. NICE guideline [NG80] 2017. Update March 2021. https://www.nice.org.uk/guidance/ng80/ (accessed 18 October 2022)

36. Sustainable Health Coalition, 2019. Care pathway for Monoclonal Antibody Therapy June 2018. https://shcoalition.org/care-pathway-for-monoclonal-antibody-therapy-2/ (accessed 18 October 2022)

37. Oxford Academic Health Science Network Accelerated Access Collaborative. Understanding opportunities to improve Severe Asthma Care in England: A National Benchmarking Exercise, March 2022 https://www.oxfordahsn.org/

38. British Lung Foundation, 2022. Chronic obstructive pulmonary disease (COPD) statistics https://statistics.blf.org.uk/copd (accessed 18 October 2022)

39. National Institute of Clinical Excellence, 2018 Chronic Obstructive Pulmonary Disease in over 16s: diagnosis and management. NICE guideline [NG115] 2018. Update July 2019. https://www.nice.org.uk/guidance/ng115 (accessed 18 October 2022)

40. Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2022. Global Strategy for prevention, diagnosis and management of COPD: 2022 Report https://goldcopd.org/2022-gold-reports-2/ (accessed 18 October 2022)

41. National Institute of Clinical Excellence, 2018 Chronic Obstructive Pulmonary Disease (acute exacerbation): antimicrobial prescribing. NICE guideline [NG114] 2018. https://www.nice.org.uk/guidance/ng114 (accessed 18 October 2022)

42. Smith D. et al. British Thoracic Society guideline for the use of long-term macrolides in adults with respiratory disease. Thorax 2020; 0:1–35. doi:10.1136/thoraxjnl-2019-213929 https://thorax.bmj.com/content/75/5/370 (accessed 18 October 2022)

43. Experts in COPD supported by GSK, 2022. The COPD Assessment Test (CAT) August 2022. Available at: https://www.catestonline.org/hcp-homepage.html (accessed 19 October 2022)

44. Medical Research Council, 2016. MRC Breathlessness Scale 1959. https://www.ukri.org/publications/mrc-breathlessness-scales-1952-and-1959/ (Accessed 19 October 2022)

45. Healthcare Improvement Scotland / Scottish Antimicrobial Prescribing Group, 2022. Penicillin Allergy De-labelling guidance. Available here: https://www.sapg.scot/guidance-qi-tools/quality-improvement-tools/penicillin-allergy-de-labelling/ (accessed 18 October 2022)

46. Poole P, Sathananthan K, Fortescue R. Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews. May 2019. Issue 5. Available at: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001287.pub6/full (accessed 18 October 2022)

47. Novartis Pharmaceuticals UK Ltd. Enezair® Breezhaler® April 2022. Available at: https://www.medicines.org.uk/emc/product/11886 (accessed 19 October2022)

48. GlaxoSmithKline UK. Trelegy Ellipta 92/55/22 micrograms inhalation powder, pre-dispensed https://www.medicines.org.uk/emc/product/8666

49. Chiesi Limited. Trimbow pMDI 87/5/9/ micrograms pressurised inhalation. July 2022. Available at: https://www.medicines.org.uk/emc/product/761/smpc (accessed 19 October 2022)

50. Chiesi Limited. Trimbow pMDI 172/5/9/ micrograms pressurised inhalation, July 2022. Available: https://www.medicines.org.uk/emc/product/13816/smpc(Accessed 19 October 2022)

51. Chiesi Limited. Trimbow NEXThaler (DPI) 88/5/9 micrograms per actuation. July 2022. https://www.medicines.org.uk/emc/product/12829/smpc (Accessed 19 October 2022)

52. AstraZeneca UK Limited. Trixeo Aerosphere 5/ 7.2/ 160 micrograms pressurised inhalation, suspension, March 2021. Available at: https://www.medicines.org.uk/emc/product/12028 (accessed 19 October 2022)

53. University of Dundee / NHS Tayside. Bronchiectasis Severity Index http://www.bronchiectasisseverity.com/15-2/ (accessed 19 October 2022)

54. Hill AT, Sullivan AL, Chalmers JD, et al. Guideline for Bronchiectasis in Adults Thorax 2019;74 (Suppl 1):1–69. https://www.brit-thoracic.org.uk/quality-improvement/guidelines/bronchiectasis-in-adults/ (accessed 19 October 2022)

55. Polverino E, Goeminne PC, McDonnell MJ, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J 2017; 50: 1700629 https://pubmed.ncbi.nlm.nih.gov/28889110/

56. British Thoracic Society, Vol10 Issue 3, 2019. ILD Registry Annual Report 2019. Available at: https://www.acprc.org.uk/Data/Resource_Downloads/BTSILDRegistryAnnualReport2019.pdf?date=01/04/2022%2011:41:01 (accessed 19 October 2022)

57. Health Improvement Scotland / Scottish Medicines Consortium, 2022. Nintedanib (Ofev®) Advice https://www.scottishmedicines.org.uk/medicines-advice/nintedanib-ofev-fullsubmission-107615/ (accessed 18 October 2022)

58. Health Improvement Scotland / Scottish Medicines Consortium, 2022. Pirfenidone (Esbriet®) Advice August 213 https://www.scottishmedicines.org.uk/medicines-advice/pirfenidone-esbriet-resubmission-83513/(accessed 18 October 2022)

59. National Institute for Clinical Excellence, 2013. Idiopathic pulmonary fibrosis in adults: diagnosis and management. NICE guideline [CG163] Update May 2017. https://www.nice.org.uk/guidance/CG163/chapter/1-Recommendations#management (accessed 18 October 2022)

60. National Institute for Clinical Excellence, 2018. Pirfenidone for treating Idiopathic pulmonary fibrosis. February 2018. Technology Appraisal guidance [TA504]. https://www.nice.org.uk/guidance/ta504 (accessed 18 October 2022)

61. National Institute for Clinical Excellence, 2016. Nintedanib for treating Idiopathic pulmonary fibrosis. January 2016. Technology Appraisal guidance [TA379]. https://www.nice.org.uk/guidance/ta379 (accessed 18 October 2022)

62. Health Improvement Scotland / Scottish Medicines Consortium, 2022. Patient Access Schemes https://www.scottishmedicines.org.uk/making-a-submission/companies/patient-access-schemes/ (accessed 19 October 2022)

63. Scottish Government, 2022. Chief Medical Officer – Annual report: 2020-2021 March 2021. https://www.gov.scot/publications/cmo-annual-report-2020-21/pages/6/(accessed 18 October 2022)

64. Lavorini F, Corrigan CJ, Barnes PJ, Dekhuijzen PR, Levy ML, Pedersen S, Roche N, Vincken W, Crompton GK; Aerosol Drug Management Improvement Team. Retail sales of inhalation devices in European countries: so much for a global policy. Respir Med. 2011 Jul;105(7):1099-103. https://pubmed.ncbi.nlm.nih.gov/21489771/ (accessed 7 November 2022)

65. British Thoracic Society. Position Statement Environment and Lung Health March 2020 https://www.brit-thoracic.org.uk/about-us/governance-documents-and-policies/position-statements/ (Accessed 19 October 2022)

66. Green Inhaler, 2022 The problem with Inhalers. Available at: The Problem with Inhalers – Green Inhaler (Accessed 19 October 2022)

67. Woodcock, A et al. Effects of switching from a metered dose inhaler to a dry powder inhaler on climate emissions and asthma control: post-hoc analysis. Thorax 2022 O;1-6 https://thorax.bmj.com/content/early/2022/01/12/thoraxjnl-2021-218088 (accessed 19 October 2022)

68. National Institute for Clinical Excellence 2021: Asthma inhalers and climate change (patient decision aid) updated September 2022 Nice guideline [NG80] https://www.nice.org.uk/guidance/ng80/resources/inhalers-for-asthma-patient-decision-aid-pdf-6727144573(accessed 19 October 2022)

69. Koura, 2021 Zephex^® 152a: reducing the carbon footprint of asthma inhalers. Available at: https://www.zephex.com/ (accessed 19 October 2022)

70. Honeywell International Inc, 2022. Honeywell Begins Production of Near- Zero Global-Warming – Potential Medical Propellant. Press release: October 2022 https://www.honeywell.com/us/en/press/2022/10/honeywell-begins-production-of-near-zero-global-warming-potential-medical-propellant (accessed 19 October 2022)

71. PrescQIPP Community Interest Company, 2018. Bulletin 295: Inhaler carbon footprint https://www.prescqipp.info/our-resources/bulletins/bulletin-295-inhaler-carbon-footprint/(accessed 19 October 2022)

72. PrescQIPP Community Interest Company. Hot Topics – Lowering the carbon footprint update https://www.prescqipp.info/news/hot-topics-lowering-the-inhaler-carbon-footprint-update/

73. Greener Practice, 2022. Why Environmentally Sustainable Practice https://www.greenerpractice.co.uk/information-and-resources/why-environmentally-sustainable-practice/ (accessed 19 October 2022)

74. Scottish Government, 2022. Effective Prescribing and Therapeutics Division. National Therapeutic Indicators – Respiratory. Update March 2022. Available at: https://scotland.shinyapps.io/nhs-prescribing-nti/ (accessed 19 October 2022)